Mounjaro’s active ingredient, tirzepatide, produces more weight loss than Ozempic’s semaglutide in clinical trials. At its highest dose, tirzepatide led to roughly 21% body weight loss over 72 weeks, while semaglutide at its weight-management dose typically produces 12% to 15%. That gap is consistent and meaningful, though both medications deliver results that were unheard of from any drug a decade ago.
The comparison gets a little more nuanced than a single number, though. Ozempic is technically a diabetes drug, and the version of semaglutide approved specifically for weight loss is sold under a different name, Wegovy, at a higher dose. Similarly, Mounjaro is approved for type 2 diabetes, while its weight-loss counterpart is called Zepbound. The molecules are the same within each pair, but the doses and approved uses differ.
How the Two Drugs Work Differently
Semaglutide mimics a single gut hormone called GLP-1. This hormone slows stomach emptying, reduces appetite, and signals fullness to the brain. Tirzepatide does the same thing but also mimics a second gut hormone, GIP. That dual action appears to be the reason tirzepatide produces greater weight loss. GIP influences how the body stores and burns fat, and activating both pathways together amplifies the appetite-suppressing and metabolic effects beyond what GLP-1 alone can do.
Both drugs are taken as a once-weekly injection, usually in the thigh, abdomen, or upper arm. You rotate the injection site each week.
Weight Loss Numbers: Head to Head
The clearest evidence for tirzepatide comes from the SURMOUNT-1 trial, which enrolled adults with obesity but without diabetes. At the maximum 15 mg dose, participants lost an average of 20.9% of their body weight over 72 weeks. The middle dose (10 mg) produced about 19.5%, and the lowest maintenance dose (5 mg) delivered roughly 15%.
Semaglutide’s landmark trial, STEP 1, used the 2.4 mg weekly dose (the Wegovy dose) and showed an average weight loss of about 14.9% over 68 weeks. Ozempic, which tops out at 2 mg and is prescribed for blood sugar control rather than weight loss, generally produces less, closer to 10% to 12%.
So if you’re comparing the weight-loss versions of each drug at their highest approved doses, tirzepatide beats semaglutide by roughly 5 to 6 percentage points. For someone who weighs 250 pounds, that’s the difference between losing about 37 pounds and losing about 52 pounds. No head-to-head trial between the two drugs at weight-loss doses has been published, but the gap across separate trials is large enough that most obesity medicine specialists consider tirzepatide the more potent option.
Dose Escalation and Timeline
Both medications start at a low dose and gradually increase to reduce side effects, especially nausea. The ramp-up schedules are similar but not identical.
Tirzepatide (Zepbound) starts at 2.5 mg, which is purely an introductory dose and not meant for long-term use. After four weeks you move to 5 mg, and from there you can increase by 2.5 mg every four weeks or longer until you reach the maximum of 15 mg. Most people reach their target dose within three to five months.
Semaglutide (Wegovy) starts at 0.25 mg and increases monthly: 0.5 mg at week five, 1.0 mg at week nine, 1.7 mg at week thirteen, and the full 2.4 mg maintenance dose at week seventeen. The escalation takes about four months, and some people stay at 1.7 mg if they can’t tolerate the highest dose.
With both drugs, the most significant weight loss happens during the first six to nine months, then gradually plateaus as your body reaches a new set point.
Side Effects Are Similar
Because both drugs target overlapping pathways, their side-effect profiles look nearly identical. The most common complaints are gastrointestinal: nausea, diarrhea, constipation, and vomiting. These tend to be worst during the first few weeks at each new dose and fade as your body adjusts.
Tirzepatide’s higher potency doesn’t necessarily mean worse side effects for everyone, but some people do find the GI symptoms more intense, particularly at the 10 mg and 15 mg doses. In the SURMOUNT-1 trial, about 5% to 7% of participants on tirzepatide discontinued due to side effects, comparable to the dropout rates seen with semaglutide.
Rare but serious risks are the same for both: pancreatitis, gallbladder problems, and a theoretical risk of a specific type of thyroid tumor seen in animal studies. Neither drug should be used during pregnancy or by anyone with a personal or family history of medullary thyroid cancer.
What Happens When You Stop
This is where the conversation shifts from “which drug is better” to “what are you signing up for.” A 2025 systematic review in The BMJ found that people who stop newer, more effective weight-loss medications regain an estimated 9.9 kg (about 22 pounds) within the first year. The models projected a return to baseline weight approximately 1.5 years after stopping treatment.
That pattern holds for both tirzepatide and semaglutide. The drugs work by continuously suppressing appetite and altering metabolic signaling. Remove the drug and those signals return to their previous state. This doesn’t mean the medications “don’t work.” It means obesity, like high blood pressure or high cholesterol, typically requires ongoing treatment to maintain results. Most people who achieve significant weight loss on either drug will need to continue it indefinitely, taper to a lower maintenance dose, or accept some degree of regain.
Cost and Access
Neither drug is cheap without insurance. List prices for both Zepbound and Wegovy run roughly $1,000 to $1,100 per month, though manufacturer savings programs and insurance coverage can bring out-of-pocket costs down significantly. Coverage varies widely: some insurers cover Wegovy but not Zepbound, or vice versa, and many plans still exclude weight-loss medications entirely.
Ozempic is sometimes prescribed off-label for weight loss because diabetes medications receive broader insurance coverage. If your doctor prescribes Ozempic rather than Wegovy, you’re getting the same molecule at a lower maximum dose, which means less weight loss but potentially easier access. Mounjaro can be prescribed off-label in the same way, though this is less common now that Zepbound is available.
Availability has also been an issue. Both drugs have experienced shortages since their popularity surged in 2023, though supply has gradually stabilized. If one medication is unavailable or not covered by your plan, the other is a strong alternative rather than a distant second choice.
Which One Is Right for You
If weight loss is your primary goal, tirzepatide has a clear edge in the data. The roughly 6 percentage point advantage translates to meaningfully more fat loss, which can make a real difference for joint health, sleep apnea, blood sugar, and cardiovascular risk. For people with a large amount of weight to lose, that extra potency matters.
Semaglutide has a longer track record and more published data on cardiovascular outcomes. Wegovy is specifically approved to reduce the risk of heart attack and stroke in people with established heart disease and obesity, a claim Zepbound does not yet carry. If cardiovascular protection is a priority alongside weight loss, that distinction could tip the decision.
In practice, the choice often comes down to insurance coverage, availability, and how your body responds. Some people tolerate one drug better than the other, and switching is common. Both produce life-changing results for most users, and “second best” in this category still outperforms every other pharmaceutical weight-loss option on the market.